Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM-336 in High-risk Smoldering Multiple Myeloma
NCT06745687Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2024
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of gamgertamig in smoldering multiple myeloma (SMM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Minimal Residual Disease Negativity. Started Dec 2024; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT06745687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745687.